Neovacs Logo

Neovacs

Biotech firm developing immunotherapies and investing in BioTech and MedTech.

ALNEV | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0004032746 (+4 more)
LEI:
9695001J9GMM5XYK6482
Country:
France
Address:
14 RUE DE LA REPUBLIQUE, 92150 SURESNES

Description

Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-23 19:00
Nouveau contrat de financement d'un montant nominal maximal de 10 MEUR sur une …
French 372.7 KB
2025-07-08 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 273.5 KB
2025-06-03 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 252.7 KB
2025-06-02 08:00
Regroupement des actions Néovacs et suspension de la faculté d'exercice des val…
French 230.9 KB
2025-05-27 21:00
Levée de fonds de 0,5 MEUR
French 231.6 KB
2025-05-16 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 230.1 KB
2025-05-06 20:00
Ajustement de la valeur nominale
French 213.4 KB
2025-05-06 08:00
Résultats annuels 2024
French 255.3 KB
2025-05-05 12:00
Levée de fonds de 1,2 MEUR
French 231.2 KB
2025-04-30 18:00
Levée de fonds de 0,25 MEUR
French 234.1 KB
2025-04-17 18:30
Levée de fonds de 0,25 M EUR
French 248.3 KB
2025-04-16 08:00
Néovacs fait le point sur des rumeurs
French 235.6 KB
2025-04-02 20:00
Ajustement de la valeur nominale
French 210.1 KB
2025-03-28 08:00
Néovacs co-organise la 1ère rencontre Française sur les Nanoparticules Lipidiqu…
French 225.9 KB
2025-03-25 08:00
Signature d'un avenant à la convention de fiducie
French 238.6 KB

Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Neovacs

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Neovacs via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.